Compare FAT & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FAT | CVKD |
|---|---|---|
| Founded | 2017 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4M | 20.7M |
| IPO Year | 2017 | 2023 |
| Metric | FAT | CVKD |
|---|---|---|
| Price | $0.37 | $7.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $10.00 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 434.9K | 81.3K |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $574,143,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.36 | $6.75 |
| 52 Week High | $6.17 | $22.90 |
| Indicator | FAT | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 21.33 | 37.10 |
| Support Level | $0.42 | $6.75 |
| Resistance Level | $0.46 | $7.75 |
| Average True Range (ATR) | 0.04 | 0.96 |
| MACD | 0.03 | -0.18 |
| Stochastic Oscillator | 1.40 | 12.87 |
FAT Brands Inc is a multi-brand restaurant franchising company. It develops, markets, acquires, and manages quick service, fast casual, casual dining, and polished casual dining restaurant concepts around the world. The company operates as a franchisor of restaurants, where the company generally does not own or operate the restaurant locations but rather generates revenue by charging franchisees an initial franchise fee as well as ongoing royalties. For some of the company's brands, it also directly owns and operates restaurant locations. Its brands include Round Table Pizza, Fatburger, Johnny Rockets, Twin Peaks, and Elevation Burger among others. Geographically, the majority of the revenue for the company is generated from the United States.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.